This is not the most recent version of the article. View current version (15 FEB 2012)

Intervention Review

You have free access to this content

Chemoprophylaxis and intermittent treatment for preventing malaria in children

  1. Martin M Meremikwu1,*,
  2. Sarah Donegan2,
  3. Ekpereonne Esu3

Editorial Group: Cochrane Infectious Diseases Group

Published Online: 21 JAN 2009

Assessed as up-to-date: 14 NOV 2007

DOI: 10.1002/14651858.CD003756.pub3

Database Title

Additional Information

How to Cite

Meremikwu MM, Donegan S, Esu E. Chemoprophylaxis and intermittent treatment for preventing malaria in children. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD003756. DOI: 10.1002/14651858.CD003756.pub3.

Author Information

  1. 1

    University of Calabar Teaching Hospital, Department of Paediatrics, Calabar, Cross River State, Nigeria

  2. 2

    Liverpool School of Tropical Medicine, International Health Group, Liverpool, Merseyside, UK

  3. 3

    University of Calabar Teaching Hospital, Effective Health Care Research Programme - Nigeria, Calabar, Nigeria

*Martin M Meremikwu, Department of Paediatrics, University of Calabar Teaching Hospital, PMB 1115, Calabar, Cross River State, Nigeria. mmeremiku@yahoo.co.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

This is not the most recent version of the article.View current version (15 Feb 2012)

View Full Article (HTML) Summary (57K)Standard (497K)Full (760K)
[Analysis 1.1]
Analysis 1.1. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 1 Clinical malaria.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 2 Severe anaemia.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 3 Death from any cause.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 4 Hospital admission for any cause.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 5 Parasitaemia.
[Analysis 1.6]
Analysis 1.6. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 6 Enlarged spleen.
[Analysis 1.7]
Analysis 1.7. Comparison 1 Antimalarial vs placebo: individually randomized trials [main analysis], Outcome 7 Impact on routine immunization: adequate protective antibodies.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Antimalarial vs placebo: cluster-randomized trials, Outcome 1 Clinical malaria.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Antimalarial vs placebo: cluster-randomized trials, Outcome 2 Severe anaemia.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Antimalarial vs placebo: cluster-randomized trials, Outcome 3 Death from any cause.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Antimalarial vs placebo: cluster-randomized trials, Outcome 4 Hospital admission for any cause.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Antimalarial vs placebo: by drug group, Outcome 1 Clinical malaria.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Antimalarial vs placebo: by drug group, Outcome 2 Severe anaemia.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Antimalarial vs placebo: by seasonality, Outcome 1 Clinical malaria.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Antimalarial vs placebo: by seasonality, Outcome 2 Severe anaemia.
[Analysis 5.1]
Analysis 5.1. Comparison 5 Intermittent treatment vs placebo: by presence of anaemia, Outcome 1 Severe anaemia.
[Analysis 6.1]
Analysis 6.1. Comparison 6 Antimalarial vs placebo: adverse events, Outcome 1 Prophylaxis.
[Analysis 6.2]
Analysis 6.2. Comparison 6 Antimalarial vs placebo: adverse events, Outcome 2 Intermittent treatment.
[Analysis 7.1]
Analysis 7.1. Comparison 7 Antimalarial vs placebo: adequately concealed trials, Outcome 1 Clinical malaria.
[Analysis 7.2]
Analysis 7.2. Comparison 7 Antimalarial vs placebo: adequately concealed trials, Outcome 2 Severe anaemia.
[Analysis 7.3]
Analysis 7.3. Comparison 7 Antimalarial vs placebo: adequately concealed trials, Outcome 3 Death from any cause.
[Analysis 8.1]
Analysis 8.1. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 1 Clinical malaria (relative risk).
[Analysis 8.2]
Analysis 8.2. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 2 Clinical malaria (incidence rate ratio).
[Analysis 8.3]
Analysis 8.3. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 3 Severe anaemia (relative risk).
[Analysis 8.4]
Analysis 8.4. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 4 Severe anaemia (incidence rate ratio).
[Analysis 8.5]
Analysis 8.5. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 5 Death from any cause (relative risk).
[Analysis 8.6]
Analysis 8.6. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 6 Death from any cause (incidence rate ratio).
[Analysis 8.7]
Analysis 8.7. Comparison 8 Antimalarial vs placebo: impact after stopping intervention, Outcome 7 Impact on routine immunization: adequate protective antibody.
View Full Article (HTML) Summary (57K)Standard (497K)Full (760K)